• Policy
• Galvus generics to be reimbursed despite exclusivity period
• by Lee, Tak-Sun Feb 22, 2022 05:55am

• Policy
• Keytruda to be reimbursed as first-line treatment for NSCLC
• by Lee, Tak-Sun Feb 22, 2022 05:54am

• Policy
• Required PMS case reports reduced for Genvoya and Descovy
• by Lee, Hye-Kyung Feb 21, 2022 05:58am

• Policy
• Pre-registration of Novavax vaccination will begin
• by Kim, Jung-Ju Feb 21, 2022 05:58am

• Policy
• Tagrisso’s succeeds in RSA renewal… 3% price cut per dose
• by Kim, Jung-Ju Feb 18, 2022 05:55am

• Policy
• What is the pledge of the presidential candidates?
• by Lee, Jeong-Hwan Feb 18, 2022 05:54am

• Policy
• Rybrevant has been approved in Korea
• by Lee, Tak-Sun Feb 17, 2022 05:52am

• Policy
• Revised the method of Rx notes for health functional foods
• by Lee, Jeong-Hwan Feb 17, 2022 05:52am

• Policy
• Lee to pledge ‘incentives for homegrown new drugs'
• by Lee, Jeong-Hwan Feb 16, 2022 05:51am

• Policy
• There's plenty of COVID-19 PO medicine, Regkirona
• by Lee, Jeong-Hwan Feb 16, 2022 05:51am